Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  stage II papillary thyroid cancer
Trial Type:  Treatment
Results 1-6 of 6 for your search:
Start Over
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00065, NCI-2013-01983, EudraCT 2013-000423-14, NCT01843062
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12154, NCI-2013-00554, 2012C0101, RU241210I, 9312, NCT01811212
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 21 to 70
Trial IDs: UW13115, NCI-2014-00833, 2014-0391, 2014-0391-CP002, NCT02138214
Vemurafenib and Iodine I 131 in Treating Patients with BRAF Mutant, Radioiodine-Refractory Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-031, NCI-2014-01210, NCT02145143
Total Thyroidectomy with or without Prophylactic Central Neck Lymph Node Dissection in Treating Patients with Low-Risk Papillary Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: Over 18
Trial IDs: 15-C-0105, NCI-2015-00583, 09-25-0099, NCT02408887
Start Over